Enablex Patent Expiration

Enablex is a drug owned by Abbvie Inc. It is protected by 2 US drug patents filed in 2013 out of which all have expired. Based on its patents and exclusivities, its generic launch date is estimated to be Aug 21, 2016. Details of Enablex's patents and their expiration are given in the table below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6106864 Pharmaceutical formulations containing darifenacin
Aug, 2016

(8 years ago)

Expired
US5096890 Pyrrolidine derivatives
Mar, 2015

(9 years ago)

Expired

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

US patents provide insights into the exclusivity only within the United States, but Enablex is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Enablex's family patents as well as insights into ongoing legal events on those patents.

Enablex's Family Patents


Family Patents

Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List


Generic Launch

Generic Release Date:

Enablex's generic launch date based on the expiry of its last outstanding patent is estimated to be Aug 21, 2016 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)

Enablex Generics:

Darifenacin Hydrobromide is the generic name for the brand Enablex. 9 different companies have already filed for the generic of Enablex, with Alembic having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Enablex's generic

How can I launch a generic of Enablex before its drug patent expiration? :

You can seek FDA approval to launch a generic drug before the expiration of Enablex's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the Enablex's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Given below are the details of the already filed Para IV certificates on Enablex -

Strength Submission Date ANDA(s) Filed First applicant approval Last patent expiry 180 day status
7.5 mg and 15 mg 22 Dec, 2008 3 13 Mar, 2015 21 Aug, 2016 Deferred





About Enablex

Enablex is a drug owned by Abbvie Inc. It is used for treating a disease of altered motility or tone of smooth muscle and urinary incontinence. Enablex uses Darifenacin Hydrobromide as an active ingredient. Enablex was launched by Abbvie in 2004.

Approval Date:

Enablex was approved by FDA for market use on 22 December, 2004.

Active Ingredient:

Enablex uses Darifenacin Hydrobromide as the active ingredient. Check out other Drugs and Companies using Darifenacin Hydrobromide ingredient

Treatment:

Enablex is used for treating a disease of altered motility or tone of smooth muscle and urinary incontinence.

Dosage:

Enablex is available in tablet, extended release form for oral use. Given below is detailed information on Dosage -

Strength Dosage Form Availability Application Pathway
EQ 15MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** TABLET, EXTENDED RELEASE Discontinued ORAL
EQ 7.5MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** TABLET, EXTENDED RELEASE Discontinued ORAL